Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease

J Thorac Oncol. 2017 May;12(5):e59-e61. doi: 10.1016/j.jtho.2017.01.027.

Authors

Eisaku Miyauchi¹, Masakazu Ichinose², Akira Inoue³

Affiliations

¹ Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: [email protected].
² Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
³ Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.

PMID: 28434520
DOI: 10.1016/j.jtho.2017.01.027

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acrylamides
Aged
Aniline Compounds
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Female
Humans
Lung Diseases, Interstitial / chemically induced*
Lung Diseases, Interstitial / genetics
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Mutation
Piperazines / adverse effects*

Substances

Acrylamides
Aniline Compounds
Piperazines
osimertinib